The Quinoline Imidoselenocarbamate EI201 Blocks the AKT/mTOR Pathway and Targets Cancer Stem Cells Leading to a Strong Antitumor Activity

Publisher： Bentham Science Publishers

E-ISSN： 1875-533x|19|18|3031-3043

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.19, Iss.18, 2012-06, pp. : 3031-3043

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Oxygen-independent Regulation of HIF-1: Novel Involvement of PI3K/ AKT/mTOR Pathway in Cancer

By  

Current Cancer Drug Targets, Vol. 13, Iss. 3, 2013-03 ,pp. : 245-251

Bentham Science Publishers

Access to resources Recommend Favorite

Homeostasis and the Importance for a Balance Between AKT/mTOR Activity and Intracellular Signaling

By  

Current Medicinal Chemistry, Vol. 19, Iss. 22, 2012-08 ,pp. : 3748-3762

Bentham Science Publishers

Access to resources Recommend Favorite

Cancer Stem Cells and Novel Targets for Antitumor Strategies

By  

Current Pharmaceutical Design, Vol. 18, Iss. 19, 2012-06 ,pp. : 2838-2849

Bentham Science Publishers

Access to resources Recommend Favorite

The Akt-mTOR Pathway in Down’s Syndrome: The Potential Use of Rapamycin/Rapalogs for Treating Cognitive Deficits

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 1, 2014-02 ,pp. : 34-40

Bentham Science Publishers

Access to resources Recommend Favorite

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

By  

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite